<DOC>
	<DOCNO>NCT01303406</DOCNO>
	<brief_summary>This Phase IIIb Double-Blind , Randomised , Placebo-Controlled Study . The aim investigate effect idebenone patient Friedreich 's ataxia . The objective PROTI study establish whether patient correctly determine treatment assignment ( placebo idebenone ) receive randomised phase trial , identify potential change symptoms activity .</brief_summary>
	<brief_title>Patient Reported Outcomes Friedreich 's Ataxia Patients After Withdrawal From Treatment With Idebenone ( PROTI )</brief_title>
	<detailed_description />
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Friedreich Ataxia</mesh_term>
	<mesh_term>Idebenone</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<criteria>Completion V5 ( Month 12 ) , V6 ( Month 18 ) , V7 ( Month 24 ) MICONOS extension study Patients opinion investigator able comply requirement study Body weight â‰¥ 25kg Negative urine pregnancy test AE course MICONOS extension study opinion investigator attributable idebenone precludes treatment idebenone Clinically significant abnormality clinical haematology biochemistry include , limited , elevation great 1.5 time upper limit normal SGOT , SGPT creatinine Parallel participation another clinical drug trial Pregnancy breastfeeding Abuse drug alcohol Any change concomitant medication within last 30 day opinion investigator intake could negatively impact study</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>randomize withdrawal</keyword>
	<keyword>idebenone</keyword>
	<keyword>friedreich 's ataxia</keyword>
	<keyword>Miconos</keyword>
	<keyword>Patient report outcome</keyword>
	<keyword>ICARS</keyword>
</DOC>